Database Query Results : Luteolin, ,

LT, Luteolin: Click to Expand ⟱

Features:

Luteolin a Flavonoid found in celery, parsley, broccoli, onion leaves, carrots, peppers, cabbages, apple skins, and chrysanthemum flowers.
-MDR1 expression, MMP-9, IGF-1 and Epithelial to mesenchymal transition.

-Note half-life 2–3 hours
BioAv low, but could be improved with Res, or blend of castor oil, kolliphor and polyethylene glycol
Pathways:
- induce ROS production in cancer cell but a few reports of reduction. Always seems to reduce ROS in normal cells.
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓
- Lowers AntiOxidant defense in Cancer Cells: NRF2↓, SOD↓, GSH↓ Catalase↓ HO1↓ GPx↓
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : IL-1β↓, TNF-α↓, IL-6↓,
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMP2↓, MMP9↓, TIMP2, IGF-1↓, VEGF↓, FAK↓, RhoA↓, NF-κB↓, CXCR4↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓, DNMT1↓, DNMT3A↓, EZH2↓, P53↑, HSP↓,
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓,
- inhibits Migration/Invasion : TumCMig↓, FAK↓, ERK↓, EMT↓, TOP1↓, TET1↓,
- inhibits glycolysis and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, LDHA↓, HK2↓, GRP78↑,
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, PDGF↓, EGFR↓, Integrins↓,
- Others: PI3K↓, AKT↓, STAT↓, Wnt↓, β-catenin↓, AMPK, ERK↓, JNK, TrxR**, - Shown to modulate the nuclear translocation of SREBP-2 (related to cholesterol).
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, Others(review target notes), Neuroprotective, Renoprotection, Hepatoprotective, CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Luteolin — Cancer vs Normal Cell Effects

Rank	Pathway / Axis	Cancer Cells	Normal Cells	Label	Primary Interpretation	Notes
1	PI3K → AKT → mTOR axis	↓ AKT / ↓ mTOR signaling	↔ adaptive suppression	Driver	Loss of survival and growth signaling	Luteolin consistently suppresses PI3K/AKT signaling, explaining growth inhibition and apoptosis sensitization
2	NF-κB signaling	↓ NF-κB activation	↓ inflammatory NF-κB tone	Driver	Suppression of inflammatory survival transcription	NF-κB inhibition is a core, repeatedly observed luteolin effect
3	Reactive oxygen species (ROS)	↑ ROS (context- & dose-dependent)	↓ ROS / buffered	Conditional Driver	Biphasic redox modulation	Luteolin can act as a pro-oxidant in cancer cells while remaining antioxidant in normal cells
4	Mitochondrial integrity / intrinsic apoptosis	↓ ΔΨm; ↑ caspase activation	↔ preserved	Secondary	Execution of intrinsic apoptosis	Mitochondrial apoptosis follows signaling and redox stress
5	STAT3 signaling	↓ STAT3 activation	↔ minimal	Secondary	Loss of proliferative and stemness signaling	STAT3 suppression contributes to reduced invasion and CSC traits
6	Cell cycle regulation	↑ G1 or G2/M arrest	↔ spared	Phenotypic	Cytostatic growth control	Cell-cycle arrest reflects upstream pathway inhibition
7	Migration / invasion (EMT, MMP axis)	↓ migration & invasion	↔	Phenotypic	Anti-metastatic phenotype	Reduced EMT and protease activity limit invasiveness

Scientific Papers found: Click to Expand⟱

1539-

Api,

LT,

Dietary flavones counteract phorbol 12-myristate 13-acetate-induced SREBP-2 processing in hepatic cells

in-vitro,

Liver,

HepG2

1,10,25uM

"highlight2" >SREBP2↓, "highlight2" >eff↑, "highlight2" >p‑MEK↓, "highlight2" >p‑ERK↓,

2596-

Api,

LT,

Natural Nrf2 Inhibitors: A Review of Their Potential for Cancer Treatment

Review,

Var,

"highlight2" >NRF2↓, "highlight2" >chemoPv↑, "highlight2" >ChemoSen↑,

2625-

Ba,

LT,

Baicalein and luteolin inhibit ischemia/reperfusion-induced ferroptosis in rat cardiomyocyte

in-vivo,

Stroke,

rat

"highlight2" >*lipid-P↓, "highlight2" >*ACSL4∅, "highlight2" >*NRF2∅, "highlight2" >*GPx4∅, "highlight2" >*Ferroptosis↓, "highlight2" >*ROS↓, "highlight2" >*MDA↓, "highlight2" >*eff↑, "highlight2" >*HO-1∅,

3633-

BBR,

LT,

Cro,

QC,

Naturally Occurring Acetylcholinesterase Inhibitors and Their Potential Use for Alzheimer's Disease Therapy

Review,

AD,

"highlight2" >*AChE↓, "highlight2" >*AChE↓,

2919-

LT,

Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence

Review,

Var,

"highlight2" >RadioS↑, "highlight2" >ChemoSen↑, "highlight2" >chemoP↑, "highlight2" >*lipid-P↓, "highlight2" >*Catalase↑, "highlight2" >*SOD↑, "highlight2" >*GPx↑, "highlight2" >*GSTs↑, "highlight2" >*GSH↑, "highlight2" >*TNF-α↓, "highlight2" >*IL1β↓, "highlight2" >*Casp3↓, "highlight2" >*IL10↑, "highlight2" >NRF2↓, "highlight2" >HO-1↓, "highlight2" >NQO1↓, "highlight2" >GSH↓, "highlight2" >MET↓, "highlight2" >p‑MET↓, "highlight2" >p‑Akt↓, "highlight2" >HGF/c-Met↓, "highlight2" >NF-kB↓, "highlight2" >Bcl-2↓, "highlight2" >SOD2↓, "highlight2" >Casp8↑, "highlight2" >Casp3↑, "highlight2" >PARP↑, "highlight2" >MAPK↓, "highlight2" >NLRP3↓, "highlight2" >ASC↓, "highlight2" >Casp1↓, "highlight2" >IL6↓, "highlight2" >IKKα↓, "highlight2" >p‑p65↓, "highlight2" >p‑p38↑, "highlight2" >MMP2↓, "highlight2" >ICAM-1↓, "highlight2" >EGFR↑, "highlight2" >p‑PI3K↓, "highlight2" >E-cadherin↓, "highlight2" >ZO-1↑, "highlight2" >N-cadherin↓, "highlight2" >CLDN1↓, "highlight2" >β-catenin/ZEB1↓, "highlight2" >Snail↓, "highlight2" >Vim↑, "highlight2" >ITGB1↓, "highlight2" >FAK↓, "highlight2" >p‑Src↓, "highlight2" >Rac1↓, "highlight2" >Cdc42↓, "highlight2" >Rho↓, "highlight2" >PCNA↓, "highlight2" >Tyro3↓, "highlight2" >AXL↓, "highlight2" >CEA↓, "highlight2" >NSE↓, "highlight2" >SOD↓, "highlight2" >Catalase↓, "highlight2" >GPx↓, "highlight2" >GSR↓, "highlight2" >GSTs↓, "highlight2" >GSH↓, "highlight2" >VitE↓, "highlight2" >VitC↓, "highlight2" >CYP1A1↓, "highlight2" >cFos↑, "highlight2" >AR↓, "highlight2" >AIF↑, "highlight2" >p‑STAT6↓, "highlight2" >p‑MDM2↓, "highlight2" >NOTCH1↓, "highlight2" >VEGF↓, "highlight2" >H3↓, "highlight2" >H4↓, "highlight2" >HDAC↓, "highlight2" >SIRT1↓, "highlight2" >ROS↑, "highlight2" >DR5↑, "highlight2" >Cyt‑c↑, "highlight2" >p‑JNK↑, "highlight2" >PTEN↓, "highlight2" >mTOR↓, "highlight2" >CD34↓, "highlight2" >FasL↑, "highlight2" >Fas↑, "highlight2" >XIAP↓, "highlight2" >p‑eIF2α↑, "highlight2" >CHOP↑, "highlight2" >LC3II↑, "highlight2" >PD-1↓, "highlight2" >STAT3↓, "highlight2" >IL2↑, "highlight2" >EMT↓, "highlight2" >cachexia↓, "highlight2" >BioAv↑, "highlight2" >*Half-Life↝, "highlight2" >*eff↑,

2923-

LT,

Luteolin induces apoptosis through endoplasmic reticulum stress and mitochondrial dysfunction in Neuro-2a mouse neuroblastoma cells

in-vitro,

NA,

"highlight2" >Apoptosis↑, "highlight2" >TumCD↑, "highlight2" >Casp12↑, "highlight2" >Casp9↑, "highlight2" >Casp3↑, "highlight2" >ER Stress↑, "highlight2" >CHOP↑, "highlight2" >GRP78/BiP↑, "highlight2" >GRP94↑, "highlight2" >cl‑ATF6↑, "highlight2" >p‑eIF2α↑, "highlight2" >MMP↓, "highlight2" >JNK↓, "highlight2" >p38↑, "highlight2" >ERK↑, "highlight2" >Cyt‑c↑,

2922-

LT,

Combination of transcriptomic and proteomic approaches helps unravel the mechanisms of luteolin in inducing liver cancer cell death via targeting AKT1 and SRC

in-vitro,

Liver,

HUH7

 12.68 µM

"highlight2" >Half-Life↝, "highlight2" >TumCCA↑, "highlight2" >AKT1↓, "highlight2" >ATF2↓, "highlight2" >NF-kB↓, "highlight2" >GSK‐3β↓, "highlight2" >cMyc↓, "highlight2" >GSTs↓, "highlight2" >TrxR1↓, "highlight2" >ROS↑,

2921-

LT,

Luteolin as a potential hepatoprotective drug: Molecular mechanisms and treatment strategies

Review,

Nor,

"highlight2" >*hepatoP↑, "highlight2" >*AMPK↑, "highlight2" >*SIRT1↑, "highlight2" >*ROS↓, "highlight2" >STAT3↓, "highlight2" >TNF-α↓, "highlight2" >NF-kB↓, "highlight2" >*IL2↓, "highlight2" >*IFN-γ↓, "highlight2" >*GSH↑, "highlight2" >*SREBP1↓, "highlight2" >*ZO-1↑, "highlight2" >*TLR4↓, "highlight2" >BAX↑, "highlight2" >Bcl-2↓, "highlight2" >XIAP↓, "highlight2" >Fas↑, "highlight2" >Casp8↑, "highlight2" >Beclin-1↑, "highlight2" >*TXNIP↓, "highlight2" >*Casp1↓, "highlight2" >*IL1β↓, "highlight2" >*IL18↓, "highlight2" >*NLRP3↓, "highlight2" >*MDA↓, "highlight2" >*SOD↑, "highlight2" >*NRF2↑, "highlight2" >*ER Stress↓, "highlight2" >*ALAT↓, "highlight2" >*AST↓, "highlight2" >*iNOS↓, "highlight2" >*IL6↓, "highlight2" >*HO-1↑, "highlight2" >*NQO1↑, "highlight2" >*PPARα↑, "highlight2" >*ATF4↓, "highlight2" >*CHOP↓, "highlight2" >*Inflam↓, "highlight2" >*antiOx↑, "highlight2" >*GutMicro↑,

2920-

LT,

Formulation, characterization, in vitro and in vivo evaluations of self-nanoemulsifying drug delivery system of luteolin

in-vitro,

Nor,

in-vivo,

Nor,

"highlight2" >BioAv↑, "highlight2" >eff↑,

2925-

LT,

Luteolin Induces Carcinoma Cell Apoptosis through Binding Hsp90 to Suppress Constitutive Activation of STAT3

in-vitro,

Cerv,

HeLa

in-vitro,

Nor,

HEK293

in-vitro,

BC,

MCF-7

"highlight2" >HSP90↓, "highlight2" >p‑STAT3↓, "highlight2" >Apoptosis↑, "highlight2" >selectivity↑,

2918-

LT,

Luteolin inhibits melanoma growth in vitro and in vivo via regulating ECM and oncogenic pathways but not ROS

in-vitro,

Melanoma,

A375

in-vivo,

Melanoma,

in-vitro,

Melanoma,

SK-MEL-28

"highlight2" >TumCG↓, "highlight2" >ROS↑, "highlight2" >ECM/TCF↓,

2917-

LT,

Rad,

Luteolin acts as a radiosensitizer in non‑small cell lung cancer cells by enhancing apoptotic cell death through activation of a p38/ROS/caspase cascade

in-vitro,

Lung,

"highlight2" >Bcl-2↓, "highlight2" >Casp3↑, "highlight2" >Casp8↑, "highlight2" >Casp9↑, "highlight2" >p‑p38↑, "highlight2" >ROS↑, "highlight2" >RadioS↑,

2916-

LT,

Antioxidative and Anticancer Potential of Luteolin: A Comprehensive Approach Against Wide Range of Human Malignancies

Review,

Var,

Review,

AD,

Review,

Park,

"highlight2" >proCasp9↓, "highlight2" >CDC2↓, "highlight2" >CycB/CCNB1↓, "highlight2" >Casp9↑, "highlight2" >Casp3↑, "highlight2" >Cyt‑c↑, "highlight2" >cycA1/CCNA1↑, "highlight2" >CDK2↓, "highlight2" >APAF1↑, "highlight2" >TumCCA↑, "highlight2" >P53↑, "highlight2" >BAX↑, "highlight2" >VEGF↓, "highlight2" >Bcl-2↓, "highlight2" >Apoptosis↑, "highlight2" >p‑Akt↓, "highlight2" >p‑EGFR↓, "highlight2" >p‑ERK↓, "highlight2" >p‑STAT3↓, "highlight2" >cardioP↑, "highlight2" >Catalase↓, "highlight2" >SOD↓, "highlight2" >*BioAv↓, "highlight2" >*antiOx↑, "highlight2" >*ROS↓, "highlight2" >*NO↓, "highlight2" >*GSTs↑, "highlight2" >*GSR↑, "highlight2" >*SOD↑, "highlight2" >*Catalase↑, "highlight2" >*lipid-P↓, "highlight2" >PI3K↓, "highlight2" >Akt↓, "highlight2" >CDK2↓, "highlight2" >BNIP3↑, "highlight2" >hTERT/TERT↓, "highlight2" >DR5↑, "highlight2" >Beclin-1↑, "highlight2" >TNF-α↓, "highlight2" >NF-kB↓, "highlight2" >IL1↓, "highlight2" >IL6↓, "highlight2" >EMT↓, "highlight2" >FAK↓, "highlight2" >E-cadherin↑, "highlight2" >MDM2↓, "highlight2" >NOTCH↓, "highlight2" >MAPK↑, "highlight2" >Vim↓, "highlight2" >N-cadherin↓, "highlight2" >Snail↓, "highlight2" >MMP2↓, "highlight2" >Twist↓, "highlight2" >MMP9↓, "highlight2" >ROS↑, "highlight2" >MMP↓, "highlight2" >*AChE↓, "highlight2" >*MMP↑, "highlight2" >*Aβ↓, "highlight2" >*neuroP↑, "highlight2" >Trx1↑, "highlight2" >ROS↓, "highlight2" >*NRF2↑, "highlight2" >NRF2↓, "highlight2" >*BBB↑, "highlight2" >ChemoSen↑, "highlight2" >GutMicro↑,

2915-

LT,

Luteolin promotes apoptotic cell death via upregulation of Nrf2 expression by DNA demethylase and the interaction of Nrf2 with p53 in human colon cancer cells

in-vitro,

Colon,

HT29

30 μM

in-vitro,

CRC,

SNU-407

30 μM

in-vitro,

Nor,

FHC

65 μM

"highlight2" >DNMTs↓, "highlight2" >TET1↑, "highlight2" >NRF2↑, "highlight2" >HDAC↓, "highlight2" >tumCV↓, "highlight2" >BAX↑, "highlight2" >Casp9↑, "highlight2" >Casp3↑, "highlight2" >Bcl-2↓, "highlight2" >ROS↓, "highlight2" >GSS↑, "highlight2" >Catalase↑, "highlight2" >HO-1↑, "highlight2" >DNMT1↓, "highlight2" >DNMT3A↓, "highlight2" >TET1↑, "highlight2" >TET3↑, "highlight2" >TET2↓, "highlight2" >P53↑, "highlight2" >P21↑,

2914-

LT,

Therapeutic Potential of Luteolin on Cancer

Review,

Var,

3–50 µM in vitro

"highlight2" >*antiOx↑, "highlight2" >*IronCh↑, "highlight2" >*toxicity↓, "highlight2" >*BioAv↓, "highlight2" >*BioAv↑, "highlight2" >DNAdam↑, "highlight2" >TumCP↓, "highlight2" >DR5↑, "highlight2" >P53↑, "highlight2" >JNK↑, "highlight2" >BAX↑, "highlight2" >cl‑Casp3↑, "highlight2" >cl‑Casp8↑, "highlight2" >cl‑Casp9↑, "highlight2" >cl‑PARP↑, "highlight2" >survivin↓, "highlight2" >cycD1/CCND1↓, "highlight2" >CycB/CCNB1↓, "highlight2" >CDC2↓, "highlight2" >P21↑, "highlight2" >angioG↓, "highlight2" >MMP2↓, "highlight2" >AEG1↓, "highlight2" >VEGF↓, "highlight2" >VEGFR2↓, "highlight2" >MMP9↓, "highlight2" >CXCR4↓, "highlight2" >PI3K↓, "highlight2" >Akt↓, "highlight2" >ERK↓, "highlight2" >TumAuto↑, "highlight2" >LC3B-II↑, "highlight2" >EMT↓, "highlight2" >E-cadherin↑, "highlight2" >N-cadherin↓, "highlight2" >Wnt↓, "highlight2" >ROS↑, "highlight2" >NICD↓, "highlight2" >p‑GSK‐3β↓, "highlight2" >iNOS↓, "highlight2" >COX2↓, "highlight2" >NRF2↑, "highlight2" >Ca+2↑, "highlight2" >ChemoSen↑, "highlight2" >ChemoSen↓, "highlight2" >IFN-γ↓, "highlight2" >RadioS↑, "highlight2" >MDM2↓, "highlight2" >NOTCH1↓, "highlight2" >AR↓, "highlight2" >TIMP1↑, "highlight2" >TIMP2↑, "highlight2" >ER Stress↑, "highlight2" >CDK2↓, "highlight2" >Telomerase↓, "highlight2" >p‑NF-kB↑, "highlight2" >p‑cMyc↑, "highlight2" >hTERT/TERT↓, "highlight2" >RAS↓, "highlight2" >YAP/TEAD↓, "highlight2" >TAZ↓, "highlight2" >NF-kB↓, "highlight2" >NRF2↓, "highlight2" >HO-1↓, "highlight2" >MDR1↓,

2913-

LT,

Luteolin induces apoptosis by impairing mitochondrial function and targeting the intrinsic apoptosis pathway in gastric cancer cells

in-vitro,

GC,

HGC27

0, 10, 20, 30, 40, 50, 60, 70, and 80 µM) for 24 h or 48 h

in-vitro,

BC,

MCF-7

in-vitro,

GC,

MKN45

"highlight2" >TumCP↓, "highlight2" >MMP↓, "highlight2" >Apoptosis↑, "highlight2" >ROS↑, "highlight2" >SOD↓, "highlight2" >ATP↓, "highlight2" >Bax:Bcl2↑, "highlight2" >TumCCA↑,

2912-

LT,

Luteolin: a flavonoid with a multifaceted anticancer potential

Review,

Var,

"highlight2" >ROS↑, "highlight2" >TumCCA↑, "highlight2" >TumCP↓, "highlight2" >angioG↓, "highlight2" >ER Stress↑, "highlight2" >mtDam↑, "highlight2" >PERK↑, "highlight2" >ATF4↑, "highlight2" >eIF2α↑, "highlight2" >cl‑Casp12↑, "highlight2" >EMT↓, "highlight2" >E-cadherin↑, "highlight2" >N-cadherin↓, "highlight2" >Vim↓, "highlight2" >*neuroP↑, "highlight2" >NF-kB↓, "highlight2" >PI3K↓, "highlight2" >Akt↑, "highlight2" >XIAP↓, "highlight2" >MMP↓, "highlight2" >Ca+2↑, "highlight2" >BAX↑, "highlight2" >Casp3↑, "highlight2" >Casp9↑, "highlight2" >Bcl-2↓, "highlight2" >Cyt‑c↑, "highlight2" >IronCh↑, "highlight2" >SOD↓, "highlight2" >*ROS↓, "highlight2" >*LDHA↑, "highlight2" >*SOD↑, "highlight2" >*GSH↑, "highlight2" >*BioAv↓, "highlight2" >Telomerase↓, "highlight2" >cMyc↓, "highlight2" >hTERT/TERT↓, "highlight2" >DR5↑, "highlight2" >Fas↑, "highlight2" >FADD↑, "highlight2" >BAD↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 61

Pathway results for Effect on Cancer / Diseased Cells:

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress ⓘ

antiOx↑, 8, Catalase↑, 5, Ferroptosis↓, 1, GPx↑, 2, GPx4∅, 1, GSH↑, 5, GSR↑, 2, GSTA1↑, 1, GSTs↑, 2, HO-1↑, 3, HO-1∅, 1, lipid-P↓, 5, MDA↓, 2, NQO1↑, 1, NRF2↓, 2, NRF2↑, 4, NRF2∅, 1, PrxII↑, 1, ROS↓, 15, SOD↑, 7,

Metal & Cofactor Biology ⓘ

IronCh↑, 1,

Mitochondria & Bioenergetics ⓘ

ATP↑, 2, p‑MEK↓, 1, p‑MKK4↑, 1, MMP↑, 2, Raf↓, 1,

Core Metabolism/Glycolysis ⓘ

ACSL4∅, 1, ALAT↓, 1, AMPK↑, 2, CREB↑, 1, LDHA↑, 1, PPARα↑, 1, PPARγ↑, 1, SIRT1↑, 2, SREBP1↓, 1,

Cell Death ⓘ

p‑Akt↓, 1, Apoptosis↓, 1, BAX↓, 1, Bax:Bcl2↓, 1, Bcl-2↑, 1, Casp1↓, 1, Casp3↓, 3, Casp9↓, 1, Casp9↑, 1, Cyt‑c↓, 1, Ferroptosis↓, 1, iNOS↓, 1, p‑JNK↓, 1, p‑p38↓, 1,

Transcription & Epigenetics ⓘ

other↓, 2,

Protein Folding & ER Stress ⓘ

CHOP↓, 1, ER Stress↓, 1, GRP78/BiP↑, 1, UPR↑, 1,

Autophagy & Lysosomes ⓘ

Beclin-1↓, 1,

DNA Damage & Repair ⓘ

p‑γH2AX↓, 1,

Proliferation, Differentiation & Cell State ⓘ

p‑ERK↓, 1, GSK‐3β↓, 2, HDAC2↓, 1, p‑mTOR↓, 1, PI3K↓, 1,

Migration ⓘ

AntiAg↑, 2, AP-1↓, 1, E-cadherin↑, 1, MMP1↓, 1, PDGF↓, 1, TXNIP↓, 1, Vim↓, 1, ZO-1↑, 1,

Angiogenesis & Vasculature ⓘ

ATF4↓, 1, NO↓, 1,

Barriers & Transport ⓘ

BBB↑, 3,

Immune & Inflammatory Signaling ⓘ

COX2↓, 2, COX2∅, 1, IFN-γ↓, 1, IL10↑, 1, IL18↓, 1, IL1β↓, 3, IL2↓, 1, IL33↓, 1, IL6↓, 3, IL8↓, 1, Inflam↓, 5, NF-kB↓, 2, p‑NF-kB↓, 1, PGE2↓, 1, TLR4↓, 1, TNF-α↓, 2,

Synaptic & Neurotransmission ⓘ

AChE↓, 3, BDNF↑, 2, tau↓, 2, p‑tau↓, 2, TrkB↑, 1,

Protein Aggregation ⓘ

Aβ↓, 3, BACE↓, 1, NLRP3↓, 1,

Drug Metabolism & Resistance ⓘ

BioAv↓, 3, BioAv↑, 1, BioAv↝, 1, eff↑, 4, Half-Life↝, 1,

Clinical Biomarkers ⓘ

ALAT↓, 1, AST↓, 1, BloodF↑, 1, GutMicro↑, 1, IL6↓, 3,

Functional Outcomes ⓘ

cardioP↑, 1, cognitive↑, 2, hepatoP↑, 1, memory↑, 1, neuroP↑, 5, RenoP↑, 1, toxicity↓, 1, toxicity↑, 1,
Total Targets: 114

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:118  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

Database Query Results : Luteolin, ,

Pathway results for Effect on Cancer / Diseased Cells:

Redox & Oxidative Stress ⓘ

Metal & Cofactor Biology ⓘ

Mitochondria & Bioenergetics ⓘ

Core Metabolism/Glycolysis ⓘ

Cell Death ⓘ

Kinase & Signal Transduction ⓘ

Transcription & Epigenetics ⓘ

Protein Folding & ER Stress ⓘ

Autophagy & Lysosomes ⓘ

DNA Damage & Repair ⓘ

Cell Cycle & Senescence ⓘ

Proliferation, Differentiation & Cell State ⓘ

Migration ⓘ

Angiogenesis & Vasculature ⓘ

Immune & Inflammatory Signaling ⓘ

Protein Aggregation ⓘ

Hormonal & Nuclear Receptors ⓘ

Drug Metabolism & Resistance ⓘ

Clinical Biomarkers ⓘ

Functional Outcomes ⓘ

Pathway results for Effect on Normal Cells:

Redox & Oxidative Stress ⓘ

Metal & Cofactor Biology ⓘ

Mitochondria & Bioenergetics ⓘ

Core Metabolism/Glycolysis ⓘ

Cell Death ⓘ

Transcription & Epigenetics ⓘ

Protein Folding & ER Stress ⓘ

Autophagy & Lysosomes ⓘ

DNA Damage & Repair ⓘ

Proliferation, Differentiation & Cell State ⓘ

Migration ⓘ

Angiogenesis & Vasculature ⓘ

Barriers & Transport ⓘ

Immune & Inflammatory Signaling ⓘ

Synaptic & Neurotransmission ⓘ

Protein Aggregation ⓘ

Drug Metabolism & Resistance ⓘ

Clinical Biomarkers ⓘ

Functional Outcomes ⓘ

Home Page